Search results for "Protease Inhibitor"

showing 10 items of 125 documents

Conditions for the Enhancing Effect of Protease Inhibitors on the Concanavalin A Induced Thymidine Response of Murine Lymphocytes

1983

Incorporation of [<sup>3</sup>H]-thymidine – [<sup>3</sup>H]-TdR – into concanavalin A (Con A) stimulated murine splenocytes and thymocytes was found to be enhanced by addition of certain concentrations of phenyl-methyl-sulfonylfluoride (PMSF), di-isopropylfluorophosphate (DFP), N-α-tosyl-<i>L</i>-lysyl-<i>L</i>-chloromethylketone (TLCK), and soybean trypsin inhibitor (SBTI). No enhancement could be observed when mononuclear cells of the peripheral blood were used, and a medium enhancement when thymocytes were applied. Furthermore, no enhancing effect of the protease inhibitors (PI) on the Con A response of murine splenocytes could be observed…

MaleIsoflurophateTime Factorsmedicine.medical_treatmentImmunologyBiologyLymphocyte ActivationTosyllysine Chloromethyl KetoneMicechemistry.chemical_compoundPhagocytosisConcanavalin AmedicineAnimalsImmunology and AllergyProtease InhibitorsMice Inbred BALB CProteaseDose-Response Relationship DrugMurine splenocytesDrug SynergismGeneral MedicineMolecular biologyKineticschemistryBiochemistryConcanavalin AImmunologybiology.proteinThymidineSpleenThymidineInternational Archives of Allergy and Immunology
researchProduct

Low Rate of Virological Failure and Maintenance of Susceptibility to HIV-1 Protease Inhibitors with First-Line Lopinavir/Ritonavir-Based Antiretrovir…

2010

Protease inhibitor (PI)-resistant HIV-1 has hardly ever been detected at failed boosted PI-based first-line antiretroviral regimens in clinical trials. However, this phenomenon has not been investigated in clinical practice. To address this gap, data from patients starting a first-line lopinavir/ritonavir (LPV/rtv)-based therapy with available baseline HIV-1 RNA load, a viral genotype and follow-up viral load after 3 and 6 months of treatment were extracted from the Italian Antiretroviral Resistance Cohort Analysis (ARCA) observational database. Based on survival analysis, 39 (7.1%) and 43 (7.8%) of the 548 examined patient cases had an HIV-1 RNA >500 and >50 copies/ml, respectively, after …

MaleLopinavir/ritonavirHIV Infectionsboosted protease inhibitorLopinavirCohort Studies0302 clinical medicineAntiretroviral Therapy Highly Activevirologic failureHIV InfectionTreatment Failure030212 general & internal medicinePyrimidinone0303 health scienceseducation.field_of_studylopinavir/ritonavirLopinavirViral LoadResistance mutationfirst-line antiretroviral therapyReverse Transcriptase Inhibitor3. Good healthTreatment OutcomeInfectious DiseasesRNA ViralReverse Transcriptase InhibitorsMedicineDrug Therapy CombinationFemaleSurvival AnalysiViral loadHumanmedicine.drugAnti-HIV AgentsPopulationPyrimidinones.Settore MED/17 - MALATTIE INFETTIVEEmtricitabinehuman immunodeficiency virus type 103 medical and health sciencesVirologyDrug Resistance Viralantiretroviral drug resistancemedicineHumansProtease inhibitor (pharmacology)educationHIV Protease InhibitorRitonavir030306 microbiologybusiness.industryAnti-HIV AgentHIV Protease InhibitorsSurvival AnalysisVirologyHIV-1RitonavirCohort Studiebusiness
researchProduct

HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors

2013

Abstract Due to error-prone RNA polymerase and the lack of proofreading mechanisms, to the spread worldwide and probable long-term presence in human population, HCV showed a high degree of inter- and intra-subtype genetic variability. Protease inhibitors (PIs), a new class of drugs, have been designed specifically on the HCV genotype 1 NS3 protease three-dimensional structure. The viral genetic barrier limits the efficacy of PIs, and fourteen loci in the HCV NS3 gene are involved in resistance to PIs. A sensitive method (15 UI/ml) for study the HCV genetic profile of 125 strains from patients naive to PIs, was developed through the use of new degenerate primers for subtype 1b. We observed t…

MaleMicrobiology (medical)Settore MED/07 - Microbiologia E Microbiologia Clinicamedicine.medical_treatmentPopulationLocus (genetics)HepacivirusIntra-subtype variabilityViral Nonstructural ProteinsBiologyMicrobiologyHCV genetic barrierNS3 sequencingDrug Resistance ViralGeneticsmedicineHumansGenetic variabilityTransversioneducationMolecular BiologyGenePhylogenyEcology Evolution Behavior and SystematicsAgedGeneticseducation.field_of_studyNS3ProteaseWild typeGenetic Variationvirus diseasesHepatitis C ChronicMiddle AgedProtease inhibitorsVirologyIFN-free therapyInfectious DiseasesMutationFemaleHCV genetic barrier; IFN-free therapy; Intra-subtype variability; NS3 sequencing; Protease inhibitors
researchProduct

Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe

2013

HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis. © 2013 The Author.

MaleMultivariate analysisDatabases FactualDrug ResistanceHIV InfectionsDrug resistance0302 clinical medicineRetrospective StudieRisk FactorsEpidemiologyGenotypepol Gene Products Human Immunodeficiency ViruOdds RatioPrevalenceImmunology and AllergyHIV Infection030212 general & internal medicinepol Gene ProductsViralMultivariate Analysimedia_common0303 health sciencesDrug Resistance Prevalence HIV-1Middle AgedResistance mutation3. Good healthReverse Transcriptase InhibitorEuropeInfectious DiseasesReverse Transcriptase InhibitorsepidemiologyFemaleMultipleHuman Immunodeficiency VirusHumanDrugAdultmedicine.medical_specialtyGenotypeEvolutionmedia_common.quotation_subjectSexual Behaviorantiretroviral therapyInfectious DiseaseBiologySettore MED/17 - MALATTIE INFETTIVEEvolution Molecular03 medical and health sciencesDatabasesSDG 3 - Good Health and Well-beingDrug Resistance Multiple ViralmedicineHumansHIV Protease InhibitorFactualRetrospective Studies030306 microbiologyRisk FactorMolecularRetrospective cohort studyOdds ratioHIV Protease InhibitorsCD4 Lymphocyte Countantiretroviral therapy; drug resistance; epidemiology; genotyping; HIV-1; Adult; CD4 Lymphocyte Count; Databases Factual; Europe; Evolution Molecular; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Mutation; Odds Ratio; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Sexual Behavior; pol Gene Products Human Immunodeficiency Virus; Drug Resistance Multiple Viral; Immunology and Allergy; Infectious Diseasesgenotypingpol Gene Products Human Immunodeficiency VirusImmunologyMultivariate AnalysisMutationHIV-1DemographyJournal of Infectious Diseases
researchProduct

Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020

2020

Data on features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children and adolescents are scarce. We report preliminary results of an Italian multicentre study comprising 168 laboratory-confirmed paediatric cases (median: 2.3 years, range: 1 day–17.7 years, 55.9% males), of which 67.9% were hospitalised and 19.6% had comorbidities. Fever was the most common symptom, gastrointestinal manifestations were frequent; two children required intensive care, five had seizures, 49 received experimental treatments and all recovered.

MalePediatricsEpidemiologyProtease InhibitorComorbiditymedicine.disease_causeClinical Laboratory TechniqueSevere Acute Respiratory SyndromeDisease OutbreaksFeces0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaCOVID-19 TestingRetrospective StudiePandemic030212 general & internal medicineViralChildCoronavirusPediatricDisease OutbreakCoinfectionHospitals PediatricSettore MED/38HospitalsDiarrheaTreatment OutcomeSARS-CoV-2 infection; children; covid-19; hydroxychloroquine; pneumonia; Adolescent; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Testing; Child; Child Preschool; Chronic Disease; Clinical Laboratory Techniques; Coinfection; Comorbidity; Coronavirus; Coronavirus Infections; Diarrhea; Disease Outbreaks; Feces; Female; Fever; Hospitals Pediatric; Humans; Immunocompromised Host; Infant; Infant Newborn; Italy; Male; Noninvasive Ventilation; Pandemics; Pneumonia Viral; Protease Inhibitors; Retrospective Studies; SARS-CoV-2; Severe Acute Respiratory Syndrome; Treatment OutcomeItalyChild PreschoolCoinfectionFemalemedicine.symptomCoronavirus InfectionsRapid CommunicationHumanDiarrheamedicine.medical_specialtyCOVID-19; ItalyhydroxychloroquineAdolescentFeverCoronaviruPneumonia ViralAntiviral Agents03 medical and health sciencesBetacoronavirusImmunocompromised Hostchildren030225 pediatricsVirologyIntensive caremedicineHumanspneumoniaProtease InhibitorsPreschoolPandemicsRetrospective StudiesAntiviral Agentchildren; covid-19; hydroxychloroquine; pneumonia; SARS-CoV-2 infection; Adolescent; Antiviral Agents; Betacoronavirus; Child; Child Preschool; Chronic Disease; Clinical Laboratory Techniques; Coinfection; Comorbidity; Coronavirus; Coronavirus Infections; Diarrhea; Disease Outbreaks; Feces; Female; Fever; Hospitals Pediatric; Humans; Immunocompromised Host; Infant; Infant Newborn; Italy; Male; Noninvasive Ventilation; Pandemics; Pneumonia Viral; Protease Inhibitors; Retrospective Studies; Severe Acute Respiratory Syndrome; Treatment OutcomeNoninvasive VentilationBetacoronaviruPandemicbusiness.industryClinical Laboratory TechniquesCoronavirus InfectionSARS-CoV-2pneumonia.SARS-CoV-2 infectionPublic Health Environmental and Occupational HealthInfant NewbornCOVID-19InfantRetrospective cohort studymedicine.diseaseNewbornComorbidityCoronavirusPneumoniaChronic DiseaseFecebusiness
researchProduct

Use of nonlinear mixed effect modeling for the intestinal absorption data: application to ritonavir in the rat.

2005

The aim of this study is to investigate in situ the mechanisms involved in the gastrointestinal absorption of ritonavir in the rat, as an animal model for preclinical studies of anti-HIV agents in vivo. Four ritonavir solutions (40, 27, 13 and 7 microM) in the presence of 1% dimethylsulfoxide (DMSO) were perfused in the small intestine of anaesthetised rats. Effects of DMSO on the intestinal permeability were investigated using solutions containing antipyrine 1.33 mM and ritonavir 7 microM with and without 1% of DMSO. Antipyrine and ritonavir transport was not modified in the presence of 1% of DMSO. The population pharmacokinetic parameters of the ritonavir intestinal transport were obtaine…

MalePopulationPharmaceutical ScienceAbsorption (skin)PharmacologyIntestinal absorptionPharmacokineticsimmune system diseasesIn vivoIntestine SmallmedicineAnimalsHumansDimethyl SulfoxideRats Wistareducationeducation.field_of_studyIntestinal permeabilityRitonavirChemistryvirus diseasesGeneral MedicineHIV Protease Inhibitorsmedicine.diseaseSmall intestineRatsPerfusionmedicine.anatomical_structureIntestinal AbsorptionNonlinear DynamicsSolubilityModels AnimalRitonavirBiotechnologymedicine.drugEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Induction of RAGE Shedding by Activation of G Protein-Coupled Receptors

2011

The multiligand Receptor for Advanced Glycation End products (RAGE) is involved in various pathophysiological processes, including diabetic inflammatory conditions and Alzheimers disease. Full-length RAGE, a cell surface-located type I membrane protein, can proteolytically be converted by metalloproteinases ADAM10 and MMP9 into a soluble RAGE form. Moreover, administration of recombinant soluble RAGE suppresses activation of cell surface-located RAGE by trapping RAGE ligands. Therefore stimulation of RAGE shedding might have a therapeutic value regarding inflammatory diseases. We aimed to investigate whether RAGE shedding is inducible via ligand-induced activation of G protein-coupled recep…

MaleReceptors Vasopressinendocrine system diseasesReceptor for Advanced Glycation End Productslcsh:MedicineHydroxamic Acids570 Life sciencesRAGE (receptor)Adenylyl cyclaseADAM10 ProteinMicePhosphatidylinositol 3-Kinaseschemistry.chemical_compoundMolecular Cell BiologyNeurobiology of Disease and RegenerationSignaling in Cellular ProcessesMembrane Receptor SignalingReceptors Immunologiclcsh:ScienceReceptorLungCellular Stress ResponsesCalcium signalingMultidisciplinaryKinaseDipeptidesHormone Receptor SignalingCell biologyMatrix Metalloproteinase 9NeurologyReceptors OxytocinGene Knockdown Techniquescardiovascular systemMatrix Metalloproteinase 2Pituitary Adenylate Cyclase-Activating PolypeptideMedicineRNA InterferenceAdenylyl CyclasesResearch ArticleSignal Transduction570 Biowissenschaftenmedicine.medical_specialtyMAP Kinase Signaling SystemADAM17 ProteinBiologyAlzheimer DiseaseCa2+/calmodulin-dependent protein kinaseInternal medicinemedicineAnimalsHumansProtease InhibitorsCalcium Signalingcardiovascular diseasesBiologyG protein-coupled receptorlcsh:RHEK 293 cellsMembrane Proteinsnutritional and metabolic diseasesCyclic AMP-Dependent Protein KinasesADAM ProteinsG-Protein SignalingHEK293 CellsEndocrinologychemistryProteolysisDementialcsh:QAmyloid Precursor Protein SecretasesMolecular Neurosciencehuman activitiesReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type INeurosciencePLoS ONE
researchProduct

Bioavailability and pharmacokinetic model for ritonavir in the rat.

2007

The aim of this study is to investigate in vivo the oral bioavailability of ritonavir and to evaluate the pharmacokinetic model that best describes the plasma concentration behavior after oral and intravenous administration. Male Wistar rats were intravenously administered at 3 mg dose of pure ritonavir and oral administered at 4.6 +/- 2.5 mg of diluted Norvir. Blood samples were taken by means of the jugular vein for a 24 h period of time. An analytical high-performance liquid chromatography (HPLC) technique was developed in order to quantify ritonavir plasma concentrations. A nonlinear modeling approach was used to estimate the pharmacokinetic parameters of interest. Results showed that a…

MaleRitonavirbiologyChemistryPharmaceutical ScienceBiological AvailabilityAbsorption (skin)PharmacologyHigh-performance liquid chromatographyModels BiologicalBioavailabilityAbsorptionRatsPharmacokineticsIn vivoEnzyme inhibitormedicinebiology.proteinAnimalsRitonavirProtease inhibitor (pharmacology)Rats Wistarmedicine.drugJournal of pharmaceutical sciences
researchProduct

Saliva electrophoretic protein profiles in infants: changes with age and impact of teeth eruption and diet transition.

2011

International audience; Objective : The objective of this study was to describe the changes in salivary protein profiles in infants between the ages of 3 and 6 months, and to evaluate the impact of teeth eruption and introduction of solid foods on such profiles. Design : 73 infants were followed longitudinally at 3 and 6 months of age. Their whole saliva proteins were separated by SDS–PAGE electrophoresis and semi-quantified by image analysis. Amylase activity was also measured on a sub-sample of the population (n=42 infants). Bands which abundance was significantly different between the two ages according to paired comparisons were identified by mass spectrometry techniques. Results : Out …

MaleSalivaTooth eruptionPhysiologyTooth Eruption0302 clinical medicineTandem Mass Spectrometry[SDV.IDA]Life Sciences [q-bio]/Food engineeringAmylaseLongitudinal StudiesProspective Studies0303 health scienceseducation.field_of_studybiologyChemistryinfantsGeneral MedicineInfant FormulaBiochemistryAmylasesSalivary CystatinsElectrophoresis Polyacrylamide GelFemaleInfant FoodIntroduction of solid foodamylaseSpectrometry Mass Electrospray IonizationproteomePopulationslivaWeaning03 medical and health sciencesWeaningHumans[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringCystatin AProtease InhibitorsCystatin BSalivary Proteins and PeptideseducationGeneral DentistrycystatinSerum Albumin030304 developmental biologyMilk HumanBeta-2 microglobulinSalivary CystatinsAlbuminInfant030206 dentistryCell BiologyDietSecretory ComponentOtorhinolaryngologySpectrometry Mass Matrix-Assisted Laser Desorption-Ionizationbiology.proteinproteinbeta 2-Microglobulinteeth eruptionChromatography LiquidFollow-Up StudiesArchives of oral biology
researchProduct

Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver …

2015

In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but they are under-represented in clinical trials. All treatment-experienced F3/4 Metavir patients who received boceprevir (BOC)+P/R in the Italian-Spanish Name Patient Program have been included in this study. Multivariate logistic regression analysis (MLR) was used to identify baseline and on-treatment predictors of SVR and adverse events (AEs). Four hundred and sixteen patients, mean age 57.7 (range 25-78 years), 70% males, 69.5% (289/416) F4, 14% (…

MaleSettore MED/09 - Medicina Internaboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Infectious Diseases; Virology; Medicine (all)Hepacivirusboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Virology; Infectious DiseasesGastroenterologyIFN-based therapy; boceprevir; cirrhosis; first-generation protease inhibitors; hepatitis Cfirst-generation protease inhibitorchemistry.chemical_compoundLiver diseaseboceprevirMedicineViralChronicSettore MED/12 - Gastroenterologiaboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy; Combination; Female; Hepacivirus; Hepatitis C; Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA; Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Infectious Diseases; Virology; Medicine (all)Medicine (all)virus diseasesHepatitis CMiddle AgedViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CInfectious DiseasesTreatment OutcomeItalyHCVCombinationRNA ViralDrug Therapy CombinationFemaleViral loadHumanAdultmedicine.medical_specialtyProlineAlpha interferonInfectious DiseaseAntiviral AgentsDrug TherapyVirologyInternal medicineBoceprevirRibavirinboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis c; IFN-based therapy; adult; aged; antiviral agents; drug therapy combination; female; hepacivirus; hepatitis c chronic; humans; interferon-alpha; italy; male; middle aged; proline; RNA viral; ribavirin; spain; treatment outcome; viral load; hepatology; infectious diseases; virologyHumansDecompensationAdverse effectAgedAntiviral AgentIFN-based therapyHepaciviruHepatologybusiness.industryRibavirincirrhosisInterferon-alphaHepatitis C Chronicmedicine.diseasedigestive system diseasesboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Loadfirst-generation protease inhibitorschemistrySpainImmunologyRNAbusinesscirrhosi
researchProduct